SEC filing record
Primary Source · SEC.gov

Red Cell Incubation Fund II, L.P.

Fund Vehicle2025 vintageRule 506(b), Section 3(c), Section 3(c)(7)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalFirst saleForm D/A · 2026-08-076 events: 1 first sale, 1 sold increased, 1 investors increasedLast filing 2026-08-07

Raised

$87M

Investors

32

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Red Cell Incubation Fund II, L.P. is a Delaware limited partnership that first filed a Form D on August 7, 2025 and most recently amended it on August 7, 2026, describing itself as a venture capital fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(7) and covers pooled investment fund interests. Red Cell Incubation Fund II, L.P. reported $86,985,000 sold from 32 investors in an offering of indefinite size as of the Form D filed August 7, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Park Lane IBS, LLC, associated with Stonehaven, LLC as the recipient of sales compensation soliciting in all states. The issuer's address of record is 1800 Tysons Blvd, Suite 900, Mclean, VA 22102.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002076816
Entity NameRed Cell Incubation Fund II, L.P.
ExemptionRule 506(b), Section 3(c), Section 3(c)(7)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising. Section 3(c) of the Investment Company Act of 1940: the issuer is a pooled investment vehicle relying on an exclusion from registration as an investment company. Section 3(c)(7) of the Investment Company Act: the fund is excluded from investment-company registration because every investor is a qualified purchaser, generally an individual with at least $5 million in investments or an institution with at least $25 million.
Entity TypeLimited Partnership
Jurisdiction of OrganizationDelaware
Issuer Address1800 Tysons Blvd, Suite 900, Mclean, VA 22102
Phone(650) 843-5000
Industry / Fund TypePooled Investment Fund · Venture Capital Fund
Investment Company ActExcluded under Section 3(c)(7) (qualified purchasers only)
Securities TypePooled investment fund interests
First Sale DateAugust 8, 2025
Filing DateAugust 7, 2026
Accession Number0002076816-26-000005
Total Offering AmountIndefinite
Total Amount Sold$86,985,000
Total Investors32
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Revenue RangeDecline to Disclose
State (Issuer Address)VA
Amendment Count2 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

6

latest Aug 7, 2026

Critical / warning

0 / 0

3 watch · 3 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

raising

Latest event First sale · Aug 7, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Fund family Part of the Red Cell Incubation Fund family: 2 vehicles across 1 generation · adviser of record Red Cell Management, LLC · full family and the filing behind each link in the terminal

Investor

  • The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
  • 6 filing events with values and deltas, latest 2026-08-07, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Adviser of Record (Form ADV)

Red Cell Management, LLC

CRD 315048 · exempt reporting adviser · lists this fund on Schedule D 7.B.(1) as a venture capital fund

Auditor named on Form ADV: Weaver And Tidwell, L.L.P. · PCAOB-registered per the adviser

From the adviser's Form ADV as loaded from the SEC bulk data, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2026-08-07: 1 related person added and 0 removed against the filing of 2025-08-07; 5 now listed. The names are in the Terminal feed.

Red Cell Incubation II GP, LLC

Director · McLean, VA

General Partner of the Issuer

Red Cell Partners, LLC

Director · McLean, VA

Manager of the General Partner of the Issuer

Grant Verstandig

Director · McLean, VA

Manager of the Manager of the General Partner of the Issuer

Roger Ferguson

Director · McLean, VA

Manager of the Manager of the General Partner of the Issuer

John Tiernan

Executive Officer · McLean, VA

President of the General Partner of the Issuer

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Park Lane IBS, LLC

Associated broker-dealer: Stonehaven, LLC (CRD 118913) · New York, NY · Soliciting in all states

Questions About Red Cell Incubation Fund II, L.P.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Red Cell Incubation Fund II, L.P.?

Red Cell Incubation Fund II, L.P. is a Delaware limited partnership that filed a Form D with the SEC on August 7, 2026 as a venture capital fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests.

Is Red Cell Incubation Fund II, L.P. legit?

AltStreet does not rate legitimacy; it reports the public record. Red Cell Incubation Fund II, L.P. filed a Form D with the SEC on August 7, 2026 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $86,985,000 sold to 32 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Red Cell Incubation Fund II, L.P. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Red Cell Incubation Fund II, L.P. claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Red Cell Incubation Fund II, L.P. raised?

Red Cell Incubation Fund II, L.P. reported $86,985,000 sold from 32 investors in an offering of indefinite size as of the Form D filed August 7, 2026.

Who can invest in Red Cell Incubation Fund II, L.P.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Red Cell Incubation Fund II, L.P.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Red Cell Incubation Fund II, L.P. and how are they paid?

The Form D names Park Lane IBS, LLC, associated with Stonehaven, LLC as the recipient of sales compensation soliciting in all states.

Who is behind Red Cell Incubation Fund II, L.P.?

The Form D lists 5 related persons: Red Cell Incubation II GP, LLC, director (General Partner of the Issuer); Red Cell Partners, LLC, director (Manager of the General Partner of the Issuer); Grant Verstandig, director (Manager of the Manager of the General Partner of the Issuer); Roger Ferguson, director (Manager of the Manager of the General Partner of the Issuer); John Tiernan, executive officer (President of the General Partner of the Issuer). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Red Cell Incubation Fund II, L.P. located?

The issuer's address on its SEC filings is 1800 Tysons Blvd, Suite 900, Mclean, VA 22102. Its phone number of record is 650-843-5000. It is organized under the laws of Delaware.

How long is the Red Cell Incubation Fund II, L.P. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

How large is Red Cell Incubation Fund II, L.P.?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.